Bessemer Group
XLRN

Bessemer Group’s Acceleron Pharma XLRN Stock Holding History

Bessemer Group’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-70
Closed -$12K – 2020
2021
Q3 		$12K Hold
70
– – ﹤0.01% 1344
2021
Q2 		$9K Hold
70
– – ﹤0.01% 1370
2021
Q1 		$9K Buy
+70
New +$9.04K ﹤0.01% 1337
2020
Q3 		– Sell
-14,300
Closed -$1.36M – 1764
2020
Q2 		$1.36M Buy
+14,300
New +$1.38M ﹤0.01% 620
2017
Q1 		– Sell
-4,755
Closed -$122K – 1962
2016
Q4 		$122K Buy
4,755
+4,639
+3,999% +$147K ﹤0.01% 1192
2016
Q3 		$4K Sell
116
-3
-3% -$99 ﹤0.01% 1680
2016
Q2 		$4K Sell
119
-1
-0.8% -$33 ﹤0.01% 1207
2016
Q1 		$3K Sell
120
-10,002
-99% -$291K ﹤0.01% 1360
2015
Q4 		$494K Buy
10,122
+9,999
+8,129% +$360K ﹤0.01% 622
2015
Q3 		$3K Hold
123
– – ﹤0.01% 1438
2015
Q2 		$4K Hold
123
– – ﹤0.01% 1406
2015
Q1 		$5K Sell
123
-11,509
-99% -$458K ﹤0.01% 1352
2014
Q4 		$454K Buy
+11,632
New +$405K ﹤0.01% 606

Bessemer Group's XLRN Position: Q4 2021 in Review

Bessemer Group sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 70 shares — an estimated $12K sold.

Bessemer Group first reported a position in XLRN in Q4 2014 and held it in 13 quarters. The position peaked at $1.36M in Q2 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.

  • Bessemer Group reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
  • Bessemer Group sold 70 Acceleron Pharma shares in Q4 2021, an estimated $12K.
  • Bessemer Group first reported a position in Acceleron Pharma in Q4 2014 and held it in 13 quarters.
  • Bessemer Group's Acceleron Pharma position peaked at $1.36M in Q2 2020.
  • 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.

Based on Bessemer Group's 13F filing for Q4 2021, filed 27 Jan 2022.